Telitacicept for Antibody–Mediated Rejection in Kidney Transplantation: A Retrospective Real–World Study
Background Antibody–mediated rejection (AMR) remains a leading cause of late kidney allograft loss due to a lack of effective therapies. Telitacicept, a recombinant TACI–Ig fusion protein neutralizing B–lymphocyte stimulator (BLyS) and a proliferation–inducing ligand (APRIL), showed efficacy in antibody–mediated autoimmune disorders, but its role in AMR remains unexplored. Methods In this single–center, retrospective, real–world study, ten kidney transplant recipients with biopsy–proven active or chronic active AMR received telitacicept for ≥ 6 months plus standard antirejection therapy and underwent follow–up biopsy within one year. Outcomes included allograft function, proteinuria, donor–specific antibody (DSA) levels, and Banff scores. Results Over a follow–up lasting more than two years, allograft function remained stable (estimated glomerular filtration rate [eGFR] change within ±20%) in 70% (7/10), with annualized eGFR slopes ranging from −3.59 to +9.34 mL/min/1.73 m²/year among responders. Four of six patients with baseline proteinuria (>1 g/24h) had sustained reductions, and serum immunoglobulins (IgG, IgM, IgA) declined significantly (P < 0.05). Circulating human leukocyte antigen (HLA) and DSA levels generally decreased at first follow–up, with variable rebound after discontinuation. Follow-up biopsies showed reductions in intimal arteritis (v), peritubular capillaritis (ptc), and C4d deposition. Five patients no longer met Banff AMR criteria. Residual microvascular inflammation persisted in four, and borderline T-cell–mediated rejection features occurred in one. Microvascular inflammation score decreased numerically (3.5 to 2.0; P = 0.063), and chronic lesions remained largely stable. Infectious complications occurred but resolved with treatment. Conclusion In this small, uncontrolled cohort, telitacicept–based therapy was associated with heterogeneous clinical and histopathological changes, warranting prospective controlled trials.
Authors
- Qianqian Ye (ORCID: https://orcid.org/0009-0005-2366-1359)
- 朱碧松
- 黄昌浩
- Meng Meng (ORCID: https://orcid.org/0000-0002-6499-5452)
- Wei Lin (ORCID: https://orcid.org/0009-0006-5068-4502)
- Weiyuan Wang
- Peng Jin
- Bo Yang
- Xiang Ding
- Lielin Wu
Institutions
- Central South University (CN)
- Hunan Cancer Hospital (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Journal of Nephrology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1093/joneph/aajag284
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00